Metabolic Syndrome X: A High-Yield USMLE Review

Metabolic syndrome (syndrome X) is a clustering of interrelated metabolic abnormalities rooted in insulin resistance. It identifies patients at high cardiovascular risk who may benefit from aggressive intervention even before frank diabetes develops. On the exam it is defined by meeting a threshold number of component criteria and frequently coexists with, or foreshadows, type 2 diabetes.

Presentation

• Central obesity, defined by increased waist circumference (>102 cm / 40 in in men, >88 cm / 35 in in women)
• Hypertension (e.g. 142/88 mmHg)
• Dyslipidemia — high triglycerides and low HDL
• Impaired fasting glucose or overt hyperglycemia
• Acanthosis nigricans, a cutaneous sign of insulin resistance

Diagnosis

• Clinical diagnosis by NCEP ATP III criteria — meeting at least three of the component abnormalities (central obesity by waist circumference, elevated blood pressure, high triglycerides, low HDL, elevated fasting glucose)
• Waist circumference measurement to capture central obesity (>102 cm / 40 in in men, >88 cm / 35 in in women) — the ATP III criterion, distinct from BMI
• Fasting glucose and HbA1c to detect impaired glucose regulation or established diabetes; the ATP III fasting glucose criterion is ≥100 mg/dL, while HbA1c ≥6.5% or fasting glucose ≥126 mg/dL indicates overt diabetes
• Fasting lipid panel documenting high triglycerides (≥150 mg/dL) and low HDL (<40 mg/dL men, <50 mg/dL women)
• Blood pressure measurement (≥130/85 mmHg) to capture hypertension
• Urine albumin-to-creatinine ratio and monofilament testing when diabetes is established, to screen for early microvascular complications (nephropathy, neuropathy)

Management

• Aggressive lifestyle intervention targeting weight loss and the underlying insulin resistance — the cornerstone of reducing progression to diabetes and cardiovascular events
• Treat each component: control hypertension, manage dyslipidemia, and address hyperglycemia
• In patients who progress to type 2 diabetes, metformin is a foundational agent (respecting eGFR thresholds), with attention to renal-protective therapy when microvascular disease is present
• Screen for and manage established microvascular complications (albuminuria, neuropathy) once diabetes is diagnosed

High-yield

• Diagnostic criteria are NCEP ATP III: ≥3 of central obesity (by waist circumference), hypertension (≥130/85 mmHg), high triglycerides (≥150 mg/dL), low HDL (<40 men, <50 women), and elevated fasting glucose (≥100 mg/dL)
• Central obesity criterion is waist circumference (>102 cm/40 in men, >88 cm/35 in women) — NOT BMI
• Metabolic syndrome = insulin-resistant patient at high cardiovascular risk, often preceding overt diabetes
• Acanthosis nigricans is a classic physical sign of insulin resistance
• Metabolic syndrome may precede diagnosis of diabetes by years — the disease is silent while microvascular damage accrues

Pitfalls

• Substituting BMI for waist circumference — the ATP III obesity criterion is central adiposity measured by waist circumference, not BMI
• Assuming metabolic syndrome is benign — it flags high cardiovascular risk and warrants intervention before diabetes develops
• Missing long-standing, undiagnosed diabetes: a patient presenting with 'metabolic syndrome plus' established microvascular disease (albuminuria, neuropathy) has likely had diabetes for years
• Treating one component in isolation rather than recognizing the clustered, insulin-resistance-driven syndrome